Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera (NCT05499013)
SLN124-004
This trial is No longer recruiting
Registration number NCT05499013
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Andrew Perkins
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR